In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Three-year major clinical outcomes of phosphorylcholine polymer- versus BioLinx polymer-zotarolimus-eluting stents: A propensity score matching study

Session Poster Session 6

Speaker Yong Hoon Kim

Event : ESC Congress 2018

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Stents
  • Session type : Poster Session

Authors : YH Kim (Chuncheon City,KR), A-Y Her (Chuncheon City,KR), S-W Rha (Seoul,KP), BG Choi (Seoul,KP), A Mashaly (Seoul,KP), Y Park (Seoul,KP), WY Jang (Seoul,KP), W Kim (Seoul,KP), JY Choi (Seoul,KP), EJ Park (Seoul,KP), JO Na (Seoul,KP), CU Choi (Seoul,KP), EJ Kim (Seoul,KP), CG Park (Seoul,KP), HS Seo (Seoul,KP)

Authors:
Y.H. Kim1 , A.-Y. Her1 , S.-W. Rha2 , B.G. Choi2 , A. Mashaly2 , Y. Park2 , W.Y. Jang2 , W. Kim2 , J.Y. Choi2 , E.J. Park2 , J.O. Na2 , C.U. Choi2 , E.J. Kim2 , C.G. Park2 , H.S. Seo2 , 1Kangwon National University Hospital - Chuncheon City - Korea Republic of , 2Korea University Guro Hospital - Seoul - Korea Republic of ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1151

Purpose: Because there are limited long-term outcome data comparing BioLinx polymer (B)-zotarolimus-eluting stents (ZESs) with phosphorylcholine polymer (P)-ZESs. We try to compare the efficacy and safety of B-ZESs with P-ZESs in patients underwent percutaneous coronary intervention (PCI) during 3-year follow-up period.

Methods: Finally, 1254 patients who underwent PCI with P-ZESs (Endeavor® [ZES-E] or Endeavor sprint® [ZES-S], n=356) or B-ZESs (Endeavor resolute® [ZES-R] or Resolute Integrity® [ZES-I], n=889) were enrolled. The primary endpoint was major adverse cardiac events (MACE); the composite of total death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), non-target vessel revascularization (Non-TVR) and the secondary endpoint was stent thrombosis (ST) up to 3 years.

Results: After PSM, two propensity-matched (PSM) groups (275 pairs, n=550, C-statistic = 0.730) were generated. During the 3-year follow-up period, the cumulative incidence of total death, cardiac death, MI, total revascularization, TLR, TVR, non-TVR, MACE (HR, 1.525; 95% CI, 0.920–2.526; p=0.101) and ST (HR, 1.248; 95% CI, 0.335–4.4649; p=0.101) were similar between P-ZESs and B-ZESs after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs. 3.8%, log rank p=0.029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs. 4.8%, log rank p=0.025) (Figure).

Conclusions: B-ZESs showed comparable safety and efficacy with P-ZESs. However, TLR rate was higher in ZES-S compared to ZES-I, TVR rates were higher in ZES-S compared with ZES-R during 3-year follow-up periods.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are